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Background: Cough is one of the most common symptoms for which patients seek medical attention from
primary care physicians and lung specialists. About 40% of the population at any one time report cough.
Cough is associated with significantly impaired health-related quality of life.
Levodropropizine is an effective and very well tolerated peripheral antitussive drug. We want to compare it to central
cough suppressants efficacy (opioids and non-opioids) that may be associated with side effects limiting their use.
Methods: After a comprehensive literature search, a meta-analysis of 7 clinical studies of levodropropizine vs. control,
including a total of 1,178 patients, was performed with the aim to evaluate the overall comparative efficacy of
levodropropizine in the pediatric and adult population.
Three electronic databases and reference list were used to search for studies that assessed the efficacy of
levodropropizine for treating cough in children and adults using as standardized efficacy parameters the cough
frequency and severity, and number of night awakenings as outcome parameters.
Results: The meta-analysis of all standardized efficacy parameters showed a highly statistically significant difference in
the overall antitussive efficacy in favor of levodropropizine vs. control treatments (p = 0.0015).
The heterogeneity test for the efficacy outcome was not statistically significant (p = 0.0534).
Seven studies met out inclusion criteria. A meta-analysis of the eligible ones showed a statistically significant difference
in the overall anti-tussive effect of levodropropizine versus control (p = 0.0015).
Conclusions: This analysis indicates that levodropropizine is an effective antitussive drug in children and adults,
with statistically significant better overall efficacy outcomes vs. central antitussive drugs (codeine, cloperastine,
dextromethorphan) in terms of reducing cough intensity and frequency, and nocturnal awakenings. This result
further reinforces the favorable benefit/risk profile of levodropropizine in the management of cough. The efficacy
of levodropropizine in the treatment of cough in children and adults is higher than that of the common
centrally-acting anti-tussive.Background
Cough is one of the most common symptoms for which
patients seek medical attention from primary care physi-
cians and lung specialists [1]. In epidemiologic studies,
up to 40% of people at any one time report cough [2].
Clinically, the etiology of cough can be broadly classi-
fied into acute and chronic as deduced from the length
of time it persists, acute cough lasting from 1 to 3 weeks
and chronic cough lasting more than 8 weeks. The most* Correspondence: alessandro.zanasi@aosp.bo.it
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creativecommons.org/publicdomain/zero/1.0/frequent causes of acute cough are viral or bacterial
upper respiratory tract infections (URTIs), while those of
chronic cough are asthma, gastro-esophageal reflux dis-
ease (GERD), chronic rhinitis, chronic bronchitis, chronic
obstructive pulmonary disease (COPD), ACE-inhibitors
treatment [3].
Regardless of whether it is acute or chronic, cough is
associated with significantly impaired health-related
quality of life, as sleep disturbance, nausea, chest pain
and lethargy frequently occur [2].
The general approach managing any cough begins
with a search for the cause of cough and treatment of
the underlying cause. However, to recognize the originticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Table 1 Characteristics of clinical studies comparing levodropropizine to controls in children
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fied, cough is refractory to specific therapy in a significant
number of patients [1]. Furthermore, empiric treatment
with antitussive agents is often needed, in particular when
associated with deterioration in the quality of life [1, 2].
The etiology of cough in children differs from that in
adults: viral URTI, protracted bacterial bronchitis and
asthma are frequently the cause of cough [2] in children.
So, the empirical approach commonly used in adults is
unsuitable for children. Clinical evaluation of cough in
children should also include an assessment of environ-
mental factors, particularly tobacco smoke, parental con-
cerns and expectations [4].
Two types of antitussive drugs are mainly available for
the management of cough: centrally acting (opioids and
non-opioids) cough suppressants and peripheral antitus-
sives. Codeine, dextromethorphan and cloperastine are
among the most common central agents that inhibit
cough primarily by their effect on the cough center.
Levodropropizine is a non-opioid agent whose periph-
eral antitussive action may result from its modulation of
sensory neuropeptide levels within the respiratory tract
[5]. In particular, levodropropizine exerts its antitussiveTable 2 Characteristics of clinical studies comparing levodrop
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Levodrop
vs. dihydreffect through an inhibitory action at the level of the air-
way sensory nerves and it has been shown to be able to in-
hibit in vitro the release of neuropeptides from C-fibers
[6]. In addition, in anaesthetized cats, it markedly reduces
the activation of C-fibres and abolishes the associated re-
flexes [7]. The activity of levodropropizine on airway sen-
sory units other than the C-fibres has not been investigated.
Centrally acting cough suppressants, although largely
used, may achieve antitussive activity at the expense of
unpleasant or intolerable side effects in adults and serious
adverse events in children: side effects like drowsiness, de-
pendency, loss of awareness, insomnia and difficulty in
breathing [2].
Furthermore, the efficacy of most antitussive drugs,
particularly those for URTI, has been challenged re-
cently; in fact, the American College of Chest Physicians
(ACCP) advises against the use of antitussive drugs in
URTI [2].
Thus, the aim of the present study was to make a
meta-analysis of clinical studies of levodropropizine
vs. control drugs to evaluate the overall comparative
efficacy of levodropropizine in the pediatric and adult
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Significant reduction in cough severity and
nocturnal awakenings with both treatments
Table 3 Absolute and standardized mean delta (levodropropizine vs. controls)
Studies, parameters Levodropropizine Controls Standardized
Mean Delta
C.I. 95% p
Mean Delta SD N Mean Delta SD N Lower Upper
Banderali, frequency −8.4 17.3 130 −7.7 13.7 126 −0.045 −0.291 0.202 0.7216
Dong Soo, frequency −1.3 1.14 38 −0.7 1.12 37 −0.525 −0.996 −0.055 0.0290
Banderali, nocturnal awakenings −1.0 2.55 132 −1 2.46 126 0.000 −0.246 0.246 1.0000
Fiocchi, nocturnal awakenings −1.06 0.81 12 −0.46 0.74 12 −0.747 −1.639 0.146 0.0966
DongSoo, severity −1.2 1.0 38 −0.7 0.99 37 −0.495 −0.967 −0.028 0.0382
De Blasio, severity −1.58 0.96 101 −1.1 1.13 60 −0.465 −0.792 −0.139 0.0055
Catena, frequency −8.3 7.5 110 −8.2 7.75 99 −0.013 −0.287 0.260 0.9250
Catena, nocturnal awakenings −2.7 1.8 80 −2.12 1.8 79 −0.321 −0.637 −0.005 0.0466
Luporini, nocturnal awakenings −1 1.5 34 −1 1.4 29 0.0 −0.508 0.508 1.0000
Allegra, severity −1.55 1 20 −0.8 1.11 20 −0.696 −1.362 −0.030 0.0410
Luporini, severity −1.2 2.92 58 −1.2 3.2 65 0.0 −0.358 0.358 1.000
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Literature search and study selection
A comprehensive systematic literature search was carried
out on the main scientific electronic databases (PubMed/
MEDLINE, EMBASE, and Cochrane Library) from their
inception throughout May 2014, to identify original clin-
ical studies of levodropropizine for the treatment of cough
in the pediatric and adult settings. We sought additional
articles from reference lists of review articles.
The inclusion criteria used to select studies were estab-
lished a priori. Only studies with a controlled design (vs.
both active control and placebo), including pediatric and
adult patients and assessing efficacy endpoints related to
cough outcomes, were selected.
Out of all the studies identified by means of our sys-
tematic literature search a total of 7 published clinical
studies conducted with levodropropizine in adults or
children met the eligibility criteria and were selected for
our meta-analysis.
These studies included a total population of 1,178 pa-
tients: four studies included 789 children and three studies
included a total of 389 adults.
Levodropropizine was compared with central antitus-
sive in five studies [8–12] and against a placebo in two
studies [13, 14].
Data analysis
Due to the small number of clinical trials in the pediatric
and adult population and the different clinical endpoints, the








−0.176 −0.282 −0.069 0.0015in order to compare the overall efficacy of levodropropizine
versus control groups. Thus, the meta-analysis was per-
formed after standardization of the overall efficacy vari-
ables assessed as endpoints in the eligible studies (i.e.
reduction in cough frequency and severity, and number
of night awakenings). For all the studies, original Abso-
lute Mean Delta was calculated as the mean differences
between baseline and final values of efficacy parameters
in both groups, with the respective (approximate) stand-
ard deviations (SD) and the number of cases (N) studied
in single treatment groups [15]. Standardized Mean Delta
was calculated by means of the original Absolute Mean
Delta (with their SD and N) and indicates a fraction or
multiple of unitary standard deviations, expressed as stan-
dardized units [16, 17].Characteristics of included studies
The study of De Blasio et al. [10] was an observational
one, carried out in 433 children (mean age 6 years) whose
aim was to evaluate the efficacy of antitussive drugs in re-
ducing the severity of acute cough associated with a URTI.
A subgroup of 161 children received antitussive treatment
with levodropropizine (N = 101) or central cough suppres-
sants (codeine or cloperastine, N = 60).
In a double blind , two parallel groups, randomized
study carried out by Kim et al. [11], the efficacy of levo-
dropropizine was compared to the central antitussive
dextromethorphan in 77 children (mean age 3 years)
with acute or chronic bronchitis with non-recurrent or
slightly recurrent cough treated for 2–3 days (oral t.i.d.
administration). In a double blind, double-dummy, two
parallel groups, randomized study Banderali et al. [8]
evaluated the efficacy of levodropropizine compared to
dropropizine, administered orally t.i.d. for 3 days, in the
management of non-productive cough in 267 pediatric
patients (2–14 years old).
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oral dose for 4 weeks on nocturnal cough was investigated
by Fiocchi et al. in a small double blind randomized study
in 12 children with asthma [14]. In a double blind, two
parallel groups , randomized study [12], Luporini et al.
evaluated the efficacy of levodropropizine compared to
dihydrocodeine (oral t.i.d. administration for 7 days) in the
treatment of non-productive cough in 140 adults with pri-
mary lung cancer or metastatic cancer of the lungs. The
double blind, double-dummy, parallel groups, randomized
trial of Catena et al. [9], evaluated the therapeutic efficacy
of levodropropizine compared to dextrometrorphan,
administered orally t.i.d. for 5 days in 209 adults with
moderate non-productive cough. The efficacy of levo-
dropropizine vs. placebo (oral t.i.d administration for
3 days) on cough severity in 40 adult patients with
bronchitis was evaluated in a double blind ,randomized ,
clinical trial carried out by Allegra et al. [13]. The main
characteristics of published studies evaluating the antitus-
sive efficacy of levodropropizine vs. control in children
and adults are summarized in Tables 1 and 2, respectively.Results
Table 3 shows the original Absolute Mean Delta (with
SD and N) calculated for each efficacy parameter (cough
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Figure 1 Meta-analysis of the efficacy of levodropropizine vs. controlin each of the eligible clinical studies, both in levodropro-
pizine and control groups in pediatric and adult patients.
The results of the standardization of different efficacy
variables, in order to make them comparable, are also
shown in Table 3 as Standardized Mean Delta (with 95%
C.I. and p between treatment groups).
The results of the meta-analysis of all standardized pa-
rameters, representing overall antitussive efficacy, showed
a highly statistically significant difference in efficacy in
favor of levodropropizine versus control treatments (in-
cluding central cough suppressants), with p of 0.0015
(Table 4). The size of antitussive effect of levodropropi-
zine vs. control treatments in the pediatric and adult
setting is shown in the overall efficacy meta-analysis
chart (Figure 1).
Concerning the estimated efficacy outcomes, levodro-
propizine was superior or equal to controls in all 7 clinical
studies, also reaching a statistically significant difference
(p < 0,05) in 4 studies.
In our meta-analysis, the test of heterogeneity for the ef-
ficacy outcome was not statistically significant (p = 0.0534).
Discussion
Cough remains a serious unmet clinical problem [2]. It is
a symptom of a range of diseases such as asthma, chronic
obstructive pulmonary disease, GERD, or other conditions
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the etiology is known, is also a challenge to even the most
experienced health care provider [1].
The American College of Chest Physicians (ACCP)
guidelines also recommend the use of peripheral cough
suppressants such as levodropropizine in adult patients
with cough due to acute or chronic bronchitis for the
short-term symptomatic relief. These guidelines state
that levodropropizine related to therapy of acute or
chronic bronchitis has got the highest level of benefit,
while the central antitussive drugs such as codeine and
dextromethorphan show a lower level of benefit [18].
Recently, the European Medicines Agency (EMA) started
a review of codeine-containing medicines when used for
cough and cold in children. In fact, codeine is converted
into morphine by CYP2D6 enzyme. It is well-known that
some patients defined as ‘CYP2D6 ultra-rapid metabolizers’
convert codeine to morphine at a faster rate, resulting in
higher levels of morphine in their blood leading to toxic
effects such as breathing difficulties. EMA is still evalu-
ating the available evidence on the benefit-risk balance
of codeine-containing medicines when they are used
for cough and cold in children [19]. FDA and MHRA
recommended against the use of OTC products for
cough and colds, as central antitussives in infants and
young children and the American Academy of Paediatrics
has advised against using dextromethorphan and codeine
for treating cough in the pediatric population [20].
The major efficacy of levodropropizine in comparison
to central antitussives has been recently demonstrated in
a meta-analysis considering only children with cough of
various origin (10).
This standardized meta-analysis of 7 published clinical
studies, despite some limitations mainly linked to the
small number of trials included in the analysis and the
different efficacy variables assessed, provides an overview
of the major comparative studies on levodropropizine in
terms of efficacy both in the pediatric and adult setting,
demonstrating a higher efficacy of levodropropizine.Conclusions
Levodropropizine is an effective antitussive drug both in
children and adults, showing statistically significant bet-
ter outcomes vs. central antitussive drugs in terms of
overall efficacy in reducing cough intensity, frequency
and night awakenings.
These positive results are particularly important con-
sidering that levodropropizine is a very well tolerated
peripheral antitussive drug, while centrally-acting cough
suppressants may be associated with serious side effects
that limit their use, thus further reinforcing the favorable
benefit/risk profile of levodropropizine in the manage-
ment of cough.Competing interests
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